Menu
Search
|

Menu

Close
X

Akcea Therapeutics Inc AKCA.OQ (NASDAQ Stock Exchange Global Select Market)

22.17 USD
+0.32 (+1.46%)
As of Feb 23
chart
Previous Close 21.85
Open 22.23
Volume 70,177
3m Avg Volume 95,355
Today’s High 22.29
Today’s Low 21.30
52 Week High 31.23
52 Week Low 8.10
Shares Outstanding (mil) 66.54
Market Capitalization (mil) 1,475.23
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
37
FY16
0
FY15
0
EPS (USD)
FY17
-2.766
FY16
-2.881
FY15
-1.214
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
39.68
8.35
Price to Book (MRQ)
vs sector
7.46
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
1.09
15.84
LT Debt to Equity (MRQ)
vs sector
0.01
12.39
Return on Investment (TTM)
vs sector
-104.75
13.63
Return on Equity (TTM)
vs sector
-215.72
15.39

EXECUTIVE LEADERSHIP

Stanley Crooke
Chairman of the Board, Since
Salary: --
Bonus: --
Paula Soteropoulos
President, Chief Executive Officer, Director, Since 2015
Salary: $412,600.00
Bonus: $340,395.00
Michael Maclean
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jeffrey Goldberg
Chief Operating Officer, Since 2015
Salary: $319,982.00
Bonus: $220,788.00
Elizabeth Hougen
Senior Vice President - Finance, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

55 Cambridge Pkwy Ste 100
CAMBRIDGE   MA   02142-1219

Phone: +1760.6032732
Site: akceatx.com/

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

SPONSORED STORIES